



# ACTAS Derma-Sifiliográficas

Full English text available at  
[www.actasdermo.org](http://www.actasdermo.org)



## ORIGINAL ARTICLE

# Mental Health Self-Assessment in Patients With Moderate to Severe Psoriasis: An Observational, Multicenter Study of 1164 Patients in Spain (The VACAP Study)

R.M. Pujol<sup>a,\*</sup>, L. Puig<sup>b</sup>, E. Daudén<sup>c</sup>, J.L. Sánchez-Carazo<sup>d</sup>, J. Toribio<sup>e</sup>,  
F. Vanaclocha<sup>f</sup>, M. Yébenes<sup>g</sup>, E. Sabater<sup>g</sup>, M.A. Casado<sup>g</sup>, M.T. Caloto<sup>h</sup>,  
B. Aragón<sup>h</sup>

<sup>a</sup> Hospital del Mar, Barcelona, Spain

<sup>b</sup> Hospital de Sant Pau, Barcelona, Spain

<sup>c</sup> Hospital La Princesa, Madrid, Spain

<sup>d</sup> Hospital General de Valencia, Valencia, Spain

<sup>e</sup> C.H.U. Santiago (Hospital Gil Casares), Santiago de Compostela, Spain

<sup>f</sup> Hospital 12 de Octubre, Madrid, Spain

<sup>g</sup> Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain

<sup>h</sup> Merck Sharp & Dohme, Outcomes Research Unit, Madrid, Spain

Received 24 October 2012; accepted 14 April 2013

Available online 7 October 2013

## KEYWORDS

Psoriasis;  
Anxiety;  
Depression;  
Hospital Anxiety and  
Depression Scale;  
HADS

## Abstract

**Background:** Poor self-assessed mental health appears to be related to the severity of psoriasis.

**Objective:** To evaluate the impact of psoriasis severity on mood and anxiety disorders.

**Methods:** A prospective, observational, multicenter study was conducted by 123 dermatologists in Spain. Patients ( $n = 164$ ; mean [SD] age, 45.11 [13.92] years; 60.8% males) with moderate to severe psoriasis were evaluated at baseline and 4 months later. Psoriasis severity was measured using the Psoriasis Area and Severity Index (PASI), with a score range of 0 (mild) to 72 (severe); body surface area involvement (BSA); and physician global assessment (PGA) scores, with a range of 1 (mild) to 7 (severe). Mental health was assessed using the Hospital Anxiety and Depression Scale (HADS), with a total possible score of 0–42 (higher scores representing worse mental health). Mean first and second visit scores were compared.

**Results:** Mean (SD) scores improved between the first and second visit as follows: 13.24 (9.50) to 5.07 (6.03) for PASI, 12.52 (7.92) to 10.78 (7.32) for overall HADS, 7.83 (4.55) to 6.85 (4.21) for the HADS anxiety subscale, and 4.72 (4.12) to 3.95 (3.76) for the HADS depression subscale ( $P < .001$  in all cases). Multivariate analyses showed that the main factors related to anxiety

\* Corresponding author.

E-mail address: [rpujol@parcdesalutmar.cat](mailto:rpujol@parcdesalutmar.cat) (R.M. Pujol).

◇ On behalf of the VACAP Study investigators (see Appendix A).

**PALABRAS CLAVE**

Psoriasis;  
 Ansiedad;  
 Depresión;  
 Escala hospitalaria de  
 ansiedad y depresión;  
 HADS

were psoriasis severity, sex, and completion of graduate studies. The independent variables included in the model for depression were psoriasis severity, sex, and psoriasis located on the head.

**Conclusions:** Reductions in disease severity improve self-assessed mood and anxiety disorders in patients with moderate to severe psoriasis.

© 2012 Elsevier España, S.L. and AEDV. All rights reserved.

## Autoevaluación de salud mental en pacientes con psoriasis moderada a grave: un estudio multicéntrico observacional de 1.164 pacientes en España (el estudio VACAP)

**Resumen**

**Antecedentes:** La gravedad de la psoriasis parece estar relacionada con una pobre autoevaluación de la salud mental.

**Objetivos:** Evaluar el impacto que tiene la gravedad de la psoriasis sobre los trastornos de ansiedad y del estado de ánimo.

**Metodología:** Estudio prospectivo, observacional y multicéntrico realizado por 123 dermatólogos en España. Los pacientes con psoriasis moderada a grave (n = 164; edad media [DE] 45,11 [13,92] años; 60,8% hombres) fueron valorados al inicio del estudio y 4 meses más tarde. Para medir la gravedad de la psoriasis se usó el Índice de Severidad y Área de Psoriasis (PASI) con un rango de puntuación entre 0 (leve) y 72 (grave); el área de superficie corporal afectada (BSA) y las puntuaciones de la evaluación global del médico (PGA) entre 1 (leve) y 7 (grave). La salud mental se evaluó utilizando la escala hospitalaria de ansiedad y depresión (HADS), con una puntuación total entre 0 y 42 (los valores más altos representan peor salud mental). Se compararon la media de las puntuaciones obtenidas en la primera y segunda visita.

**Resultados:** La media (DE) de las puntuaciones mejoraron entre la primera y la segunda visita de la siguiente manera: de 13,24 (9,50) a 5,07 (6,03) para el PASI; de 12,52 (7,92) a 10,78 (7,32) para el HADS global, de 7,83 (4,55) a 6,85 (4,21) para el HADS subescala de ansiedad y de 4,72 (4,12) a 3,95 (3,76) para el HADS subescala de depresión ( $P < 0,001$  en todos los casos). El análisis multivariante mostró que los principales factores relacionados con la ansiedad fueron la gravedad de la psoriasis, el género y la finalización de los estudios de licenciatura. Las variables independientes incluidas en el modelo de estudio para la depresión fueron la gravedad de la psoriasis, el género y la psoriasis localizada en la cabeza.

**Conclusiones:** La reducción en la gravedad de la enfermedad mejora la autoevaluación de los trastornos del estado de ánimo y de la ansiedad en pacientes con psoriasis de moderada a grave.

© 2012 Elsevier España, S.L. y AEDV. Todos los derechos reservados.

**Introduction**

Psoriasis is a common chronic inflammatory skin disease whose duration and clinical characteristics vary from patient to patient. Its etiology is unknown, but certain genetic and environmental factors that appear to be related to the development of psoriasis have been identified.<sup>1</sup> The relationships between these factors are complex because genetic and environmental factors interact in the development of the different forms of the disease.<sup>2,3</sup>

Several studies have reported impaired health-related quality of life (HRQOL) in patients with psoriasis,<sup>4,5</sup> with the greatest impact seen in social relationships and psychological well-being. To understand these effects, it is necessary to consider that plaques (or scales) may cover the entire skin surface and are sometimes difficult to conceal, causing embarrassment, low self-esteem, and body image problems. Therefore, patients with psoriasis may experience difficulty with positive social interactions, and as a consequence, have impaired mental health.

The impairment of psychological well-being in patients with psoriasis and the complex relationship between

disease severity and psychological outcomes are well documented.<sup>6,7</sup> Symptoms of anxiety and depression are common,<sup>5-8</sup> but the severity of psychological outcomes is better correlated with self-assessed severity measures of the disease.<sup>9</sup>

Self-assessment questionnaires that evaluate psychological comorbidities are commonly administered to assess different diseases, and numerous HRQOL measures include items or dimensions for the assessment of mental health. The EuroQol 5D questionnaire, for instance, has an item that assesses anxiety and depression,<sup>10</sup> and the Short Form 36 Health Survey also has dimensions that assess mental and emotional disturbance.<sup>11,12</sup> One of the most widely used tools to assess psychological comorbidities, however, is the Hospital Anxiety and Depression Scale (HADS),<sup>13</sup> which is a reliable, sensitive, and easily administered instrument<sup>14</sup> that has been validated in Spain.<sup>15</sup>

The purpose of this study was to evaluate the most common psychological symptoms in patients with psoriasis (namely, anxiety and mood symptoms) and to demonstrate the effects of improvements in disease severity on psychological well-being.

## Methods

### Design

This was a prospective, observational, multicenter study in which patients were recruited by 123 dermatologists throughout Spain within the VACAP Study (Assessment of the health-related quality of life and resource consumption in patients with moderate to severe plaque psoriasis). The patients were assessed during 2 visits: at baseline and after 4 months. The study was approved by the appropriate ethics and clinical research board. The patients were recruited consecutively at outpatient clinics. At the first visit, they were informed of the main objectives of the study and asked to provide their written informed consent to participation. The case report form comprised 2 sections. The first (completed by the dermatologists) collected demographic and clinical data relating to the patient and the second (completed by the patients) contained the quality of life questionnaire.

### Patients

A total of 1217 patients with moderate to severe psoriasis were recruited. The inclusion criteria were a diagnosis of moderate to severe plaque-type psoriasis, an age of over 18 years, and provision of informed consent to participate in the study. Exclusion criteria were a diagnosis of psoriatic arthritis, participation in a clinical trial, and inability to read or understand the questionnaires and thus to fulfill the requirements of the study protocol. A diagnosis of moderate to severe psoriasis was made if the patients fulfilled 1 of the following criteria: (1) a Psoriasis Area and Severity Index (PASI) score of over 10 (range, 0–72), (2) a physician global assessment (PGA) score of 5 or more (range, 1–7), (3) body surface area involvement (BSA) of over 10%, and (4) any clinical indication for systemic treatment.

### Assessment of psoriasis severity

Psoriasis severity was measured by the participating dermatologists using 3 scores: PASI, PGA, and BSA.

### Measures of mental health

The HADS questionnaire was used for the assessment of mental health. HADS is a self-administered questionnaire designed to detect the presence and severity of mood and anxiety disorders.<sup>13</sup> It is composed of 14 items grouped into 2 subscales: the HADS anxiety scale (HADS-A) and the HADS depression scale (HADS-D). Each subscale consists of 7 items with a possible score of 0–3. The final score is the sum of all items, i.e., a maximum of 21 on each subscale and a total possible score of 42. The HADS questionnaire has different cutoff scores to discern the likelihood of a psychiatric disorder. In this study, we used the cutoff of 12 used by Herrero et al.<sup>15</sup> in their validation of the scale in Spain as an indicator of psychiatric morbidity on screening. For the screening of depressive and anxiety disorders, the optimal cutoff score was 5 for HADS-D and 8 for HADS-A.

**Table 1** Demographic characteristics of study population.<sup>a</sup>

Mean (SD) age, y	45.11 (13.92)
Mean (SD) age at onset of psoriasis, y	26.08 (14.19)
Sex	
Men	710 (60.8)
Women	454 (39.2)
Educational level	
None	48 (4.1)
Primary school	463 (39.8)
Secondary school	397 (34.1)
University	256 (22.0)
Work status	
Employed	793 (68.1)
Unemployed	76 (6.5)
Homemaker	119 (10.2)
Retired	159 (13.7)
Retired due to illness	17 (1.5)

<sup>a</sup> Data shown as number (%) of patients unless otherwise specified.

### Statistical analyses

Databases were generated and statistical analyses were performed using Predictive Analytics Software 18.0 (PASW Statistics 18.0). Descriptive statistics were calculated as means, variance, SD, range, median, 95% CI, and 5% trimmed mean for all questionnaire and scale scores. Categorical data were calculated as frequency distributions and percentages. Missing values were not included in the statistical analyses. Comparisons between means were performed with the *t* test or the nonparametric Mann–Whitney *U* test, and comparisons of frequency distributions were performed with the Pearson  $\chi^2$  test or the Fisher exact test, where a  $2 \times 2$  contingency table was applicable. The level of statistical significance was set at  $\alpha = .05$ .

Linear regression analysis was carried out to evaluate the relationship between demographic and clinical characteristics and psychological comorbidities. The dependent variables were the difference in HADS-A and HADS-D scores between the first and second visit. Independent variables in the model were included in a stepwise, algorithmic fashion, with an inclusion criterion of  $P = .05$  and an exit criterion of  $P = .10$ . Categorical variables were transformed into dummy variables.

## Results

### Clinical data

In total, 1164 patients provided the necessary information for the questionnaires at the 2 outpatient visits. The mean (SD) age of the patients was 45.11 (13.92) years, and a majority were male (60.8%); 68.1% were employed at the time of the study and 36.1% were receiving biological therapy. The most common comorbidities were metabolic disorders (32.7%) and mental (or neurological) disorders (32.0%). The demographic and clinical data are presented in [Tables 1 and 2](#), respectively.

**Table 2** Clinical characteristics of study population.

	No. (%)
<i>Patients receiving treatment between the first and second outpatient visit</i>	932 (80.1)
Topical treatment	624 (53.6)
Biological therapy	420 (36.1)
Conventional systemic treatment	321 (27.6)
Phototherapy	164 (14.1)
Other	204 (17.5)
<i>Overall associated diseases</i>	539 (46.3)
Immune diseases	242 (20.8)
Cancer	74 (6.4)
Heart and cardiovascular disease	327 (28.1)
Dermatologic disorders	29 (2.5)
Infections	144 (12.4)
Blood and hematological diseases	31 (2.7)
Metabolic disorders	381 (32.7)
Mental/neurological disorders	372 (32.0)
Rheumatic and joint diseases	51 (4.4)
Renal disease	43 (3.7)
Respiratory disease	88 (7.6)
Other	95 (8.2)

The mean PASI was 13.24 (9.50) at the first visit and 5.07 (6.03) at the second visit ( $P < .001$ ). The percentage of patients with severe psoriasis decreased from 17.8% at baseline to 3.1% at the end of the study. Similarly, the proportion of patients with moderate to severe psoriasis also decreased (from 41.3% to 11.9%). All these differences were significant

( $P < .001$ ) and indicate an improvement in the severity of psoriasis. The data are summarized in [Table 3](#).

There was also an improvement in mean PGA scores between the first and second visit (4.93 [1.32] vs 3.27 [1.53],  $P < .001$ ). According to BSA scores, 48.1% of patients had over 10% skin surface involvement at the first visit, but this had dropped to 14.6% by the second visit ( $P < .001$ ).

Between the first and the second visit, 80.1% of patients received treatment for their psoriasis (biological therapy in 35.7% of cases).

### Mental health assessment

Mean overall mental health scores (HADS) were 12.52 (7.91) at the first visit and 10.78 (7.32) at the second visit. The HADS-A score was higher than the HADS-D score at the first visit, but both scores had decreased by the second visit. The HADS-A score was 7.83 (4.54) at baseline and 6.85 (4.21) at the end of the study, while the HADS-D score was 4.72 (4.12) and 3.95 (3.76), respectively. The differences were significant ( $P < .001$ ) in all cases. Using the cutoffs established by Herrero et al.,<sup>15</sup> at baseline 44.6% of patients had some form of psychiatric comorbidity, 39.8% had scores consistent with depression, and 37.7% had scores consistent with anxiety. These percentages had decreased by the second visit to 36.6%, 29.9%, and 30.6%, respectively ( $P < .001$  in all cases). The HADS scores are summarized in [Table 3](#).

Examination of the independent contribution of variables suggested that the main factors related to anxiety were severity of psoriasis (measured by difference in PASI between visits) ( $\beta = .307$ ,  $P < .001$ ), sex ( $\beta = .090$ ,  $P = .023$ ),

**Table 3** Results of psoriasis severity assessment tools and the Hospital Anxiety and Depression Scale (HADS).

	First visit	Second visit	P value
<i>PASI</i>			
Mean (SD) score	13.24 (9.50)	5.07 (6.03)	<.001
Mild disease	40.4	85.0	
Moderate disease	41.3	11.9	
Severe disease	18.3	3.1	
<i>PGA</i>			
Mean (SD) score	4.93 (1.33)	3.27 (1.53)	<.001
Mild disease, % of patients	13.5	57.1	
Moderate disease, % of patients	51.0	33.7	
Severe disease, % of patients	35.5	9.2	
<i>BSA</i>			
Mild disease, % of patients	10.8	48.2	<.001
Moderate disease, % of patients	41.1	37.2	
Severe disease, % of patients	47.6	14.6	
<i>Mean (SD) total HADS score</i>	12.52 (7.91)	10.78 (7.32)	<.001
Total HADS score >12, % of patients	44.3	36.6	
<i>Mean (SD) HADS-A score</i>	7.85 (4.54)	6.85 (4.21)	<.001
HADS-A score >8, % of patients	39.8	30.6	
<i>Mean HADS-D score</i>	4.72 (4.12)	3.95 (3.76)	<.001
Mean HADS-D score >5, % of patients	37.7	29.9	

**Abbreviations:** BSA, body surface area; HADS-A, HADS anxiety subscale; HADS-D, HADS depression subscale; PASI, Psoriasis Area and Severity Index; PGA; physician global assessment.

**Table 4** Multivariate linear regression analysis results for HADS anxiety subscale (HADS-A).

Model summary	R <sup>2</sup>	Adjusted R <sup>2</sup>	P value
HADS-A <sup>a</sup> = PASI <sup>b</sup> + sex <sup>c</sup> + university	0.107	.102	<.001
Variables	$\beta$ (standardized coefficients)		
PASI <sup>b</sup>	0.307		<.001
Sex <sup>c</sup>	0.090		.023
University	0.082		.039

*Abbreviations:* HADS, Hospital Anxiety and Depression Scale; PASI, Psoriasis Area and Severity Index.

<sup>a</sup> HADS-A = HADS-A at second visit – HADS-A at first visit.

<sup>b</sup> PASI = PASI at second visit – PASI at first visit.

<sup>c</sup> Sex coded as 0 for female and 1 for male.

and the completion of graduate studies ( $\beta = .082$ ,  $P = .039$ ). The remaining variables were excluded using a stepwise algorithm. The results of the multivariate analysis with HADS-A as the dependent variable are shown in [Table 4](#).

Evaluation of the contribution of variables to depression suggested that the main related factors were severity of psoriasis ( $\beta = .217$ ,  $P < .001$ ), sex ( $\beta = .099$ ,  $P = .015$ ), and psoriasis located on the head ( $\beta = -0.090$ ,  $P = .027$ ). The results of the multivariate analysis with HADS-D as the dependent variable are shown in [Table 5](#).

## Discussion

The importance of psychological well-being in outcomes research has garnered interest in recent years, and has been explored in several chronic conditions, including cancer,<sup>16,17</sup> diabetes,<sup>18</sup> chronic heart failure,<sup>19</sup> and chronic pain.<sup>20</sup>

The results of the current study confirm the presence of psychological symptoms in psoriasis, with an improvement in disease severity being accompanied by an improvement in psychological well-being. The comorbidity of psychological disorders in psoriasis patients was confirmed by 2 sources of data: the clinical data collected and the results of the HADS questionnaire. Our findings support previous reports that anxiety and depression are mental components of severe psoriasis.<sup>5,8,21</sup>

The complexity of the relationship between skin diseases and psychological disorders was highlighted in a study by Magin et al.<sup>9</sup> that examined psychological comorbidities in different skin diseases. The authors concluded that the relationship is complex and should be reanalyzed, and that personality traits may be a factor in this complexity, either

as independent or dependent variables. They evaluated both hypotheses using the introversion/extraversion and neuroticism scales of the short form of the Eysenck Personality Inventory.<sup>22</sup>

An alternative interpretation of personality involvement in psychological disturbance in psoriasis patients is the evaluation of coping strategies and alexithymia traits. The alexithymia trait has an important weighting, and in a study by Fortune et al.<sup>23</sup> it is related to a higher anxiety score, as measured by HADS. It is likely that this factor was an important component in explaining the findings of the current study, and it could, at least in part, explain the effect of different psychological outcomes in diseases such as psoriasis. It is likely that alexithymia interacts with psoriasis severity as a moderator factor.

The stigmatization experience is another important factor to consider when interpreting our results. Feelings of stigmatization are primarily related to the management of visible affected regions. As our results suggest, patients with psoriasis in visible areas have an increased level of depression,<sup>24</sup> and there have been reports of a positive relationship between the objective severity of psoriasis or visibility of skin lesions and depressive symptoms.<sup>21</sup>

A multivariate sensitivity analysis showed a sex-specific effect on psoriasis morbidity. Women were more likely to have anxiety and depression problems than men; this might be a fact because they are affected to a greater degree by impaired body image due to psoriasis. A tendency toward a higher rate of mood and anxiety disorders among women has been observed and recorded in previous publications on psoriasis<sup>24,25</sup> and other dermatological diseases.<sup>26</sup>

The current study shows that an improvement in psoriasis severity is accompanied by an improvement in associated

**Table 5** Multivariate linear regression analysis results for HADS depression subscale (HADS-D).

Model summary	R <sup>2</sup>	Adjusted R <sup>2</sup>	P value
HADS-D <sup>a</sup> = PASI <sup>b</sup> + sex <sup>c</sup> + psoriasis on head	0.065	0.060	<.001
Variables	$\beta$ (standardized coefficients)		
PASI <sup>b</sup>	0.213		<.001
Sex <sup>c</sup>	0.099		.015
Psoriasis on head	-0.090		.027

*Abbreviations:* HADS, Hospital Anxiety and Depression Scale; PASI, Psoriasis Area and Severity Index.

<sup>a</sup> HADS-D = HADS-D at second visit – HADS-D first visit.

<sup>b</sup> PASI = PASI at second visit – PASI at first visit.

<sup>c</sup> Sex coded as 0 for female and 1 for male.

psychological disorders. Hence, treatment of psoriasis is important for improving psychological disturbances in psoriasis patients. In our study, we observed an improvement in the patients' mental health at the second visit. Managing the illness and the patient's personality are important in understanding psychological outcomes. Some patients need psychological or psychiatric assistance, which may be independent of psoriasis treatment. A key factor in evaluating whether or not a patient needs such assistance is the patient's own perception of the severity of their illness.<sup>22</sup> Because PASI is generally not a reliable predictor of depression or anxiety,<sup>21</sup> it is important to screen psoriatic patients for the presence of psychological comorbidities.

The current study, which is one of the largest of its kind to be published, assesses general health using real-life data in a series of patients with psoriasis. Its main limitation is the lack of a control group at the beginning of treatment. Our results therefore must be interpreted with caution. The improvement in the severity of psoriasis at the second outpatient visit is clear. However, we cannot clearly establish whether this was due to treatment alone. It is also likely that the fact that a high percentage of patients were receiving biological therapy contributed to this improvement. Of further note is the lack of data on psychological status at the beginning of the study. The high comorbidity of mental and neurological disorders in this study supports the proposed relationship between psoriasis severity and mental health. However, we are not able to define when these comorbidities appeared, i.e., before, after, or during the initial onset of psoriasis. Although we cannot confirm a causal relationship between the severity of psoriasis and mental health, our results do indicate a certain relationship. It may be necessary to differentiate the objective clinical severity of disease from the subjective perceptions of patients.

The present study shows that psoriasis has an important impact on mental health and confirms the presence of depressive and anxiety symptomatology in patients. The relationship between the symptoms and the illness is complex; certain personality traits need to be taken into account, and psychological disturbance due to the illness needs to be managed. It is clear that psoriasis impairs mental health, but further studies are needed to investigate whether other variables are involved in the relationship between the severity of disease and psychological disturbance.

## Ethical disclosures

**Protection of human and animal subjects.** The authors declare that the procedures followed were in accordance with the regulations of the responsible Clinical Research Ethics Committee and in accordance with those of the World Medical Association and the Helsinki Declaration.

**Confidentiality of data.** The authors declare that they followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their informed consent in writing to participate in that study.

**Right to privacy and informed consent.** The authors obtained the informed consent of the patients and/or individuals mentioned in the article. The author for correspondence is in possession of these documents.

## Conflicts of interest

This study received an unconditional grant from Schering-Plough. The authors confirm independence from the funding body in matters of study design, analysis, and interpretation of the data, report writing, and submission for publication.

## Acknowledgments

The authors thank Covadonga Torres of Pharmacoeconomics and Outcomes Research Iberia (PORIB) for her assistance with the statistical analysis and the writing of this article.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.ad.2013.04.014>.

## References

1. Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. *Br J Nurs*. 2008;17:284–90.
2. Elder JT, Henseler T, Christophers E, Voorhees JJ, Nair RP. Of genes and antigens: the inheritance of psoriasis. *J Invest Dermatol*. 1994;103:150s–3s.
3. Barker J. Genetic aspects of psoriasis. *Clin Exp Dermatol*. 2001;26:321–5.
4. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. *Arch Dermatol*. 2001;137:280–4.
5. Bouguéon K, Misery L. Depression and psoriasis. *Ann Dermatol Venereol*. 2008;135:S254–8.
6. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146:891–5.
7. Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drinking habits. *Dermatol Ther*. 2010;23:174–80.
8. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. *Int J Dermatol*. 1993;32:188–90.
9. Magin PJ, Pond CD, Smith WT, Watson AB, Goode SM. A cross-sectional study of psychological morbidity in patients with acne, psoriasis and atopic dermatitis in specialist dermatology and general practices. *J Eur Acad Dermatol Venereol*. 2008;22:1435–44.
10. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16:199–208.
11. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*. 1993;31:247–63.
12. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care*. 1994;32:40–66.

13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand*. 1983;67:361–70.
14. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res*. 2002;52:69–77.
15. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the HADS in a Spanish population. *Gen Hosp Psychiatry*. 2003;25:277–83.
16. Singer S, Helge D, Dietz A, Hornemann B, Koscielny S, Oeken J, et al. Screening for mental disorders in laryngeal cancer patients: a comparison of 6 methods. *Psychooncology*. 2008;17:280–6.
17. Arving C, Glimelius B, Brandberg Y. Four weeks of daily assessments of anxiety, depression and activity compared to a point assessment with the Hospital Anxiety and Depression Scale. *Qual Life Res*. 2008;17:95–104.
18. Almawi W, Tamim H, Al-Sayed N, Arekat MR, Al-Khateeb GM, Bager A, et al. Association of comorbid depression, anxiety, and stress disorders with Type 2 diabetes in Bahrain, a country with a very high prevalence of Type 2 diabetes. *J Endocrinol Invest*. 2008;31:1020–4.
19. Pelle AJ, Gidron YY, Szabó BM, Denollet J. Psychological predictors of prognosis in chronic heart failure. *J Card Fail*. 2008;14:341–50.
20. Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. *J Pain*. 2008;9:883–91.
21. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis, and psoriasis. *Br J Dermatol*. 1998;139:846–50.
22. Eysenck SB, Eysenck HJ. An improved short questionnaire for the measurement of extraversion and neuroticism. *Life Sci*. 1964;305:1103–9.
23. Fortune DG, Richards HL, Griffiths CEM, Main JC. Psychological stress, distress and disability in patients with psoriasis. Consensus and variation in the contribution of illness perceptions, coping and alexithymia. *Br J Clin Psychol*. 2002;41:157–74.
24. Schmid-Ott G, Künsebeck HW, Jäger B, Sittig U, Hofste N, Ott R, et al. Significance of the stigmatization experience of psoriasis patients: a 1-year follow-up of the illness and its psychosocial consequences in men and women. *Acta Derm Venereol*. 2005;85:27–32.
25. Finzi A, Colombo D, Caputo A, Andreassi L, Chimenti S, Vena G, et al., PSYCHAE Study Group. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. *J Eur Acad Dermatol Venereol*. 2007;21:1161–9.
26. Moberg C, Alderling M, Meding B. Hand eczema and quality of life: a population-based study. *Br J Dermatol*. 2009;161:397–403.